The French Gaucher's disease registry: Clinical characteristics, complications and treatment of 562 patients

Orphanet Journal of Rare Diseases

Volumn 7, Issue 1, 2012, Pages

  Stirnemann, Jérôme ^a,b,c,d,w   Vigan, Marie ^a,b   Hamroun, Dalil ^e   Heraoui, Djazia ^c,f   Rossi Semerano, Linda ^g   Berger, Marc G ^h   Rose, Christian ⁱ   Camou, Fabrice ^j   De Roux Serratrice, Christine ^k   Grosbois, Bernard ^l   Kaminsky, Pierre ^m   Robert, Alain ⁿ   Caillaud, Catherine ^c,o   Froissart, Roselyne ^p   Levade, Thierry ^q   Masseau, Agathe ^r   Mignot, Cyril ^c,s,t   Sedel, Frédéric ^c,s   Dobbelaere, Dries ^u   Vanier, Marie T ^a   Valayanopoulos, Vassili ^v   Fain, Olivier ^d   Fantin, Bruno ^b,f   De Villemeur, Thierry Billette ^c,t   Mentré, France ^a,b   Belmatoug, Nadia ^c,f   more..

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Referral Center for Lysosomal Diseases (RCLD)   (France)

^d UNIVERSITÉ PARIS 13   (France)

^e HÔPITAL ARNAUD DE VILLENEUVE   (France)

^f BEAUJON HOSPITAL   (France)

^g BICÊTRE HOSPITAL   (France)

^h UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

ⁱ HÔPITAL SAINT VINCENT DE PAUL   (France)

^j HÔPITAL SAINT ANDRÉ   (France)

^k HÔPITAL SAINT JOSEPH   (France)

^l SERVICE DE RHUMATOLOGIE   (France)

^m CHU NANCY BRABOIS   (France)

ⁿ HÔPITAL DES ENFANTS   (France)

^o Institut Cochin   (France)

^p HOSPICES CIVILS DE LYON   (France)

^q CHU PURPAN   (France)

^r HÔTEL DIEU   (France)

^s PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^t ARMAND TROUSSEAU HOSPITAL   (France)

^u LILLE UNIVERSITY HOSPITAL   (France)

^v HÔPITAL NECKER ENFANTS MALADES   (France)

^w GENEVA UNIVERSITY HOSPITALS   (Switzerland)

more..

Author keywords

Bone events; Enzyme replacement therapy; French Gaucher's Disease Registry

Indexed keywords

IMIGLUCERASE; MIGLUSTAT; TALIGLUCERASE ALFA; VELAGLUCERASE ALFA;

ABDOMINAL PAIN; ANEMIA; ARTICLE; ASTHENIA; AVASCULAR NECROSIS; BLEEDING; BONE DISEASE; BONE INFARCT; BONE MARROW BIOPSY; BONE PAIN; CAUSE OF DEATH; CLINICAL FEATURE; DIAGNOSTIC TEST; DISEASE REGISTRY; ENZYME DEFECT; ENZYME REPLACEMENT; FEMALE; FOLLOW UP; FRANCE; GAUCHER DISEASE; GENE MUTATION; GENOTYPING TECHNIQUE; HEPATOMEGALY; HUMAN; INCIDENCE; LABORATORY TEST; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MORTALITY; MYELOMA; NEUROLOGICAL COMPLICATION; OSTEOSARCOMA; PARKINSON DISEASE; PATHOLOGIC FRACTURE; PIGMENTATION; PULMONARY HYPERTENSION; RADIODIAGNOSIS; SPLENECTOMY; SPLENOMEGALY; THROMBOCYTOPENIA; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; FRANCE; GAUCHER DISEASE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; SPLENECTOMY; YOUNG ADULT;

EID: 84867134063     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-7-77     Document Type: Article

References (46)

1. Metabolism of glucocerebrosides. II. Evidence of an enzymatic deficiency in Gaucher's disease. Brady RO, Kanfer JN, Shapiro D, Biochem Biophys Res Commun 1965 18 221 225 10.1016/0006-291X(65)90743-6 14282020
2. Lysosomal storage disorders in the newborn. Staretz-Chacham O, Lang TC, LaMarca ME, Krasnewich D, Sidransky E, Pediatrics 2009 123 1191 1207 10.1542/peds.2008-0635 19336380
3. Immunochemical characterization of two activator proteins stimulating enzymic sphingomyelin degradation in vitro. Absence of one of them in a human Gaucher disease variant. Christomanou H, Aignesberger A, Linke RP, Biol Chem Hoppe Seyler 1986 367 879 890 10.1515/bchm3.1986.367.2.879 3024666
4. Molecular and cell biology of acid beta-glucosidase and prosaposin. Qi X, Grabowski GA, Prog Nucleic Acid Res Mol Biol 2001 66 203 239 11051765
5. Recent clinical progress in Gaucher disease. Grabowski GA, Curr Opin Pediatr 2005 17 519 524 10.1097/01.mop.0000172702.33128.19 16012266 (Pubitemid 41104070)
6. Gaucher disease. Beutler E, Arch Intern Med 1999 159 881 882 10.1001/archinte.159.8.881 10219937 (Pubitemid 29200318)
7. Parkinsonism in Gaucher's disease type 1: ten new cases and a review of the literature. Kraoua I, Stirnemann J, Ribeiro MJ, Rouaud T, Verin M, Annic A, Rose C, Defebvre L, Remenieras L, Schupbach M, et al. Mov Disord 2009 24 1524 1530 10.1002/mds.22593 19513999
8. Type 2 Gaucher disease: 15 new cases and review of the literature. Mignot C, Doummar D, Maire I, de Villemeur TB, Brain Dev 2006 28 39 48 10.1016/j.braindev.2005.04.005 16485335 (Pubitemid 43042437)
9. Perinatal lethal Gaucher disease: a distinct phenotype along the neuronopathic continuum. Eblan MJ, Goker-Alpan O, Sidransky E, Fetal Pediatr Pathol 2005 24 205 222 10.1080/15227950500405296 16396828 (Pubitemid 43879267)
10. Perinatal-lethal Gaucher disease. Mignot C, Gelot A, Bessieres B, Daffos F, Voyer M, Menez F, Fallet Bianco C, Odent S, Le Duff D, Loget P, et al. Am J Med Genet A 2003 120 338 344 (Pubitemid 37063768)
11. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. Hollak CE, van Weely S, van Oers MH, Aerts JM, J Clin Invest 1994 93 1288 1292 10.1172/JCI117084 8132768
12. Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease. Deegan PB, Moran MT, McFarlane I, Schofield JP, Boot RG, Aerts JM, Cox TM, Blood Cells Mol Dis 2005 35 259 267 10.1016/j.bcmd.2005.05.005 16125420 (Pubitemid 41267058)
13. Elevation of serum angiotensin-converting enzyme in Gaucher's disease. Lieberman J, Beutler E, N Engl J Med 1976 294 1442 1444 10.1056/ NEJM197606242942609 179000
14. Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients. Zimran A, Kay A, Gelbart T, Garver P, Thurston D, Saven A, Beutler E, Medicine (Baltimore) 1992 71 337 353 10.1097/00005792-199211000-00002
15. Gaucher disease. Beutler E, Blood Rev 1988 2 59 70 10.1016/0268-960X(88) 90009-4 3289655
16. Serum ferritin concentration in Gaucher's disease. Morgan MA, Hoffbrand AV, Laulicht M, Luck W, Knowles S, Br Med J (Clin Res Ed) 1983 286 1864 10.1136/bmj.286.6381.1864 (Pubitemid 13100172)
17. Elevation of serum acid phosphatase in Gaucher's disease. Tuchman LR, Suna H, Carr JJ, Journal of Mount Sinai Hospital 1956 23 227 229
18. Tartrate-resistant acid phosphatase staining of monocytes in Gaucher disease. Troy K, Cuttner J, Reilly M, Grabowski G, Desnick R, Am J Hematol 1985 19 237 244 10.1002/ajh.2830190305 4014224 (Pubitemid 15033405)
19. Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease. Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, Mankin HJ, Murray GJ, Parker RI, Argoff CE, et al. N Engl J Med 1991 324 1464 1470 10.1056/NEJM199105233242104 2023606
20. Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience. Zimran A, Altarescu G, Philips M, Attias D, Jmoudiak M, Deeb M, Wang N, Bhirangi K, Cohn GM, Elstein D, Blood 2010 115 4651 4656 10.1182/blood-2010-02-268649 20299511
21. Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system. Shaaltiel Y, Bartfeld D, Hashmueli S, Baum G, Brill-Almon E, Galili G, Dym O, Boldin-Adamsky SA, Silman I, Sussman JL, et al. Plant Biotechnol J 2007 5 579 590 10.1111/j.1467-7652.2007.00263.x 17524049 (Pubitemid 47196361)
22. Substrate reduction therapy of glycosphingolipid storage disorders. Aerts JM, Hollak CE, Boot RG, Groener JE, Maas M, J Inherit Metab Dis 2006 29 449 456 10.1007/s10545-006-0272-5 16763917 (Pubitemid 43880650)
23. Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease. Hollak CE, Vom Dahl S, Aerts JM, Belmatoug N, Bembi B, Cohen Y, Collin-Histed T, Deegan P, van Dussen L, Giraldo P, et al. Blood Cells Mol Dis 2010 44 41 47 10.1016/j.bcmd.2009.09.006 19804996
24. The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, Rosenbloom BE, Scott CR, Wappner RS, Weinreb NJ, Zimran A, Arch Intern Med 2000 160 2835 2843 10.1001/archinte.160.18.2835 11025794
25. Report of the Spanish Gaucher's disease registry: clinical and genetic characteristics. Giraldo P, Pocovi M, Perez-Calvo J, Rubio-Felix D, Giralt M, Haematologica 2000 85 792 799 10942924
26. Mapping the genetic and clinical characteristics of Gaucher disease in the Iberian Peninsula. Giraldo P, Alfonso P, Irun P, Gort L, Chabas A, Vilageliu L, Grinberg D, Sa Miranda CM, Pocovi M, Orphanet J Rare Dis 2012 7 17 10.1186/1750-1172-7-17 22429443
27. Phenotypic and genotypic heterogeneity in Gaucher disease type 1: a comparison between Brazil and the rest of the world. Sobreira E, Pires RF, Cizmarik M, Grabowski GA, Mol Genet Metab 2007 90 81 86 10.1016/j.ymgme.2006.08. 009 16996765 (Pubitemid 44856291)
28. Clinical and molecular characteristics of Japanese Gaucher disease. Eto Y, Ida H, Neurochem Res 1999 24 207 211 10.1023/A:1022553819241 9972866 (Pubitemid 29067961)
29. Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults. Mistry PK, Weinreb NJ, Kaplan P, Cole JA, Gwosdow AR, Hangartner T, Blood Cells Mol Dis 2011 46 66 72 10.1016/j.bcmd.2010.10.011 21112800
30. The incidence of parkinsonism in patients with type 1 gaucher disease: data from the ICGG gaucher registry. Rosenbloom B, Balwani M, Bronstein JM, Kolodny E, Sathe S, Gwosdow AR, Taylor JS, Cole JA, Zimran A, Weinreb NJ, Blood Cells Mol Dis 2011 46 95 102 10.1016/j.bcmd.2010.10.006 21067946
31. Neuronopathic gaucher disease: demographic and clinical features of 131 patients enrolled in the international collaborative gaucher group neurological outcomes subregistry. Tylki-Szymanska A, Vellodi A, El-Beshlawy A, Cole JA, Kolodny E, J Inherit Metab Dis 2010 33 339 346 10.1007/s10545-009-9009-6 20084461
32. Life expectancy in Gaucher disease type 1. Weinreb NJ, Deegan P, Kacena KA, Mistry P, Pastores GM, Velentgas P, Vom Dahl S, Am J Hematol 2008 83 896 900 10.1002/ajh.21305 18980271
33. Phenotypic heterogeneity of N370S homozygotes with type I Gaucher disease: an analysis of 798 patients from the ICGG Gaucher Registry. Fairley C, Zimran A, Phillips M, Cizmarik M, Yee J, Weinreb N, Packman S, J Inherit Metab Dis 2008 31 738 744 10.1007/s10545-008-0868-z 18979180
34. A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase. Weinreb NJ, Taylor J, Cox T, Yee J, Vom Dahl S, Am J Hematol 2008 83 890 895 10.1002/ajh.21280 18819093
35. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease. Wenstrup RJ, Kacena KA, Kaplan P, Pastores GM, Prakash-Cheng A, Zimran A, Hangartner TN, J Bone Miner Res 2007 22 119 126 17032149 (Pubitemid 46032604)
36. Beta-glucosidase assays in the diagnosis of Gaucher's disease. Daniels LB, Glew RH, Clin Chem 1982 28 569 577 6804115 (Pubitemid 12147478)
37. Bone events and evolution of biologic markers in Gaucher disease before and during treatment. Stirnemann J, Belmatoug N, Vincent C, Fain O, Fantin B, Mentre F, Arthritis Res Ther 2010 12 156 10.1186/ar3111 20696071
38. Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis. Mistry PK, Deegan P, Vellodi A, Cole JA, Yeh M, Weinreb NJ, Br J Haematol 2009 147 561 570 10.1111/j.1365-2141.2009.07872.x 19732054
39. Gaucher's disease: clinical features and natural history. Cox TM, Schofield JP, Baillieres Clin Haematol 1997 10 657 689 10.1016/S0950-3536(97) 80033-9 9497857 (Pubitemid 28022202)
40. The N370S mutation in the glucocerebrosidase gene of Portuguese type 1 Gaucher patients: linkage to the PvuII polymorphism. Lacerda L, Amaral O, Pinto R, Aerts J, Sa Miranda MC, J Inherit Metab Dis 1994 17 85 88 10.1007/BF00735401 8051940 (Pubitemid 24110976)
41. The risk of Parkinson's disease in type 1 Gaucher disease. Bultron G, Kacena K, Pearson D, Boxer M, Yang R, Sathe S, Pastores G, Mistry PK, J Inherit Metab Dis 2010 33 167 173 10.1007/s10545-010-9055-0 20177787
42. Effect of enzyme replacement therapy on gammopathies in Gaucher disease. Brautbar A, Elstein D, Pines G, Abrahamov A, Zimran A, Blood Cells Mol Dis 2004 32 214 217 10.1016/j.bcmd.2003.10.007 14757437 (Pubitemid 38147719)
43. Gaucher disease and monoclonal gammopathy: a report of 17 cases and impact of therapy. Grosbois B, Rose C, Noel E, de Roux Serratrice C, Dobbelaere D, Gressin V, Cherin P, Hartmann A, Javier RM, Clerson P, et al. Blood Cells Mol Dis 2009 43 138 139 10.1016/j.bcmd.2009.04.002 19427246
44. Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature. De Fost M, Out TA, de Wilde FA, Tjin EP, Pals ST, van Oers MH, Boot RG, Aerts JF, Maas M, Vom Dahl S, Hollak CE, Ann Hematol 2008 87 439 449 10.1007/s00277-008- 0441-8 18274746
45. Polyclonal B-cell lymphocytosis and hypergammaglobulinemia in patients with Gaucher disease. Marti GE, Ryan ET, Papadopoulos NM, Filling-Katz M, Barton N, Fleischer TA, Rick M, Gralnick HR, Am J Hematol 1988 29 189 194 10.1002/ajh.2830290403 3263798 (Pubitemid 19004117)
46. Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study. Sims KB, Pastores GM, Weinreb NJ, Barranger J, Rosenbloom BE, Packman S, Kaplan P, Mankin H, Xavier R, Angell J, et al. Clin Genet 2008 73 430 440 10.1111/j.1399-0004.2008.00978.x 18312448 (Pubitemid 351517258)